• 1
    Roncarolo, M. G., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K. and Levings, M. K., Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 2006. 212: 2850.
  • 2
    Groux, H., Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 2003. 75: 8S12S.
  • 3
    Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J. T. and Whiteside, T. L., A unique subset of CD4+CD25highFoxp3+T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 2007. 13: 43454354.
  • 4
    Bergmann, C., Strauss, L., Wang, Y., Szczepanski, M. J., Lang, S., Johnson, J. T. and Whiteside, T. L., T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin. Cancer Res. 2008. 14: 37063715.
  • 5
    Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M. et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004. 10: 942949.
  • 6
    Trinchieri, G., Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin. Immunol. 1995. 7: 8388.
  • 7
    Screpanti, V., Wallin, R. P., Grandien, A. and Ljunggren, H. G., Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol. Immunol. 2005. 42: 495499.
  • 8
    Moretta, L. and Moretta, A., Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004. 23: 255259.
  • 9
    Biassoni, R., Cantoni, C., Marras, D., Giron-Michel, J., Falco, M., Moretta, L. and Dimasi, N., Human natural killer cell receptors: insights into their molecular function and structure. J. Cell Mol. Med. 2003. 7: 376387.
  • 10
    Wu, J. D., Higgins, L. M., Steinle, A., Cosman, D., Haugk, K. and Plymate, S. R., Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 2004. 114: 560568.
  • 11
    Ghiringhelli, F., Menard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E. et al., CD4+CD25+regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 2005. 202: 10751085.
  • 12
    Smyth, M. J., Teng, M. W., Swann, J., Kyparissoudis, K., Godfrey, D. I. and Hayakawa, Y., CD4+CD25+T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 2006. 176: 15821587.
  • 13
    Bergmann, C., Strauss, L., Zeidler, R., Lang, S. and Whiteside, T. L., Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol. Immunother. 2007. 56: 14291442.
  • 14
    Battaglia, M., Stabilini, A., Migliavacca, B., Horejs-Hoeck, J., Kaupper, T. and Roncarolo, M. G., Rapamycin promotes expansion of functional CD4+CD25+FOXP3+regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 2006. 177: 83388347.
  • 15
    Groux, H., O'Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries, J. E. and Roncarolo, M. G., A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997. 389: 737742.
  • 16
    Astier, A. L., Meiffren, G., Freeman, S. and Hafler, D. A., Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 2006. 116: 32523257.
  • 17
    Raulet, D. H., Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 2003. 3: 781790.
  • 18
    Raulet, D. H. and Guerra, N., Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 2009. 9: 568580.
  • 19
    Zhou, H., Chen, L., You, Y., Zou, L. and Zou, P., Foxp3-transduced polyclonal regulatory T cells suppress NK cell functions in a TGF-beta dependent manner. Autoimmunity 2010. 43: 299307.
  • 20
    Meadows, S. K., Eriksson, M., Barber, A. and Sentman, C. L., Human NK cell IFN-gamma production is regulated by endogenous TGF-beta. Int. Immunopharmacol. 2006. 6: 10201028.
  • 21
    Konjevic, G., Mirjacic Martinovic, K., Vuletic, A. and Babovic,N., In-vitro IL-2 or IFN-alpha-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients. Melanoma Res. 2010. 20: 459467.
  • 22
    Forte, P., Lilienfeld, B. G., Baumann, B. C. and Seebach, J. D., Human NK cytotoxicity against porcine cells is triggered by NKp44 and NKG2D. J. Immunol. 2005. 175: 54635470.
  • 23
    Frimpong-Boateng, K., van Rooijen, N. and Geiben-Lynn, R., Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+T cell immune response by the cytokine TGF-beta. PLoS One 2010. 5: e12281.
  • 24
    Giroux, M., Yurchenko, E., St-Pierre, J., Piccirillo, C. A. and Perreault, C., T regulatory cells control numbers of NK cells and CD8alpha+immature dendritic cells in the lymph node paracortex. J. Immunol. 2007. 179: 44924502.
  • 25
    Ralainirina, N., Poli, A., Michel, T., Poos, L., Andres, E., Hentges, F. and Zimmer, J., Control of NK cell functions by CD4+CD25+regulatory T cells. J. Leukoc. Biol. 2007. 81: 144153.
  • 26
    Barao, I., Hanash, A. M., Hallett, W., Welniak, L. A., Sun, K., Redelman, D., Blazar, B. R. et al., Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+regulatory T cells. Proc. Natl. Acad. Sci. USA 2006. 103: 54605465.
  • 27
    Shimizu, J., Yamazaki, S. and Sakaguchi, S., Induction of tumor immunity by removing CD25+CD4+T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999. 163: 52115218.
  • 28
    Herberman, R. B., Cancer immunotherapy with natural killer cells. Semin. Oncol. 2002. 29: 2730.
  • 29
    Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay Nel, H., Mosseri, V. et al., Prognostic value of tumor-infiltrating CD4+T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 2006. 12: 465472.
  • 30
    Correale, P., Rotundo, M. S., Del Vecchio, M. T., Remondo, C., Migali, C., Ginanneschi, C., Tsang, K. Y. et al., Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J. Immunother. 2010. 33: 435441.
  • 31
    Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E. et al., High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006. 108: 29572964.
  • 32
    Alvaro, T., Lejeune, M., Salvado, M. T., Bosch, R., Garcia, J. F., Jaen, J., Banham, A. H. et al., Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 2005. 11: 14671473.
  • 33
    Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C. and Iacopetta,B., Tumor-infiltrating FOXP3+T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 2009. 27: 186192.
  • 34
    Nishikawa, H. and Sakaguchi, S., Regulatory T cells in tumor immunity. Int. J. Cancer 2010. 127: 759767.
  • 35
    Dannull, J., Su, Z., Rizzieri, D., Yang, B. K., Coleman, D., Yancey, D., Zhang, A. et al., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005. 115: 36233633.
  • 36
    Berntsen, A., Brimnes, M. K., thor Straten, P. and Svane, I. M., Increase of circulating CD4+CD25highFoxp3+regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J. Immunother. 2010. 33: 425434.
  • 37
    Jacobs, J. F., Punt, C. J., Lesterhuis, W. J., Sutmuller, R. P., Brouwer, H. M., Scharenborg, N. M., Klasen, I. S. et al., Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 2010. 16: 50675078.
  • 38
    Zimmer, J., Andres, E. and Hentges, F., NK cells and Treg cells: a fascinating dance cheek to cheek. Eur. J. Immunol. 2008. 38: 29422945.
  • 39
    Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L. and Spies, T., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999. 285: 727729.
  • 40
    Roy, S., Barnes, P. F., Garg, A., Wu, S., Cosman, D. and Vankayalapati, R., NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J. Immunol. 2008. 180: 17291736.
  • 41
    Cao, X., Cai, S. F., Fehniger, T. A., Song, J., Collins, L. I., Piwnica-Worms, D. R. and Ley, T. J., Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007. 27: 635646.
  • 42
    Vacca, P., Cantoni, C., Vitale, M., Prato, C., Canegallo, F., Fenoglio, D., Ragni, N. et al., Crosstalk between decidual NK and CD14+myelomonocytic cells results in induction of Tregs and immunosuppression. Proc. Natl. Acad. Sci. USA 2010. 107: 1191811923.
  • 43
    Heo, D. S., Snyderman, C., Gollin, S. M., Pan, S., Walker, E., Deka, R., Barnes, E. L. et al., Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res. 1989. 49: 51675175.
  • 44
    Busche, A., Goldmann, T., Naumann, U., Steinle, A. and Brandau, S., Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum. Gene Ther. 2006. 17: 135146.
  • 45
    Aktas, E., Kucuksezer, U. C., Bilgic, S., Erten, G. and Deniz, G., Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 2009. 254: 149154.